Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia

American Journal of Hematology

Volumn 86, Issue 10, 2011, Pages 860-862

  Auerbach, Michael ^a,b   Pappadakis, Jennifer A ^c   Bahrain, Huzefa ^a   Auerbach, Sarah A ^a   Ballard, Harold ^d   Dahl, Naomi V ^c  

^a Auerbach Hematology Oncology   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Watson Laboratories Inc   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON DEXTRAN; LOW MOLECULAR WEIGHT IRON DEXTRAN; METHYLPREDNISOLONE; PARACETAMOL; TRANSFERRIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; BACKACHE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; HEADACHE; HEMATOLOGICAL PARAMETERS; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; LETTER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PREMEDICATION; PRIORITY JOURNAL; SEX DIFFERENCE; TRANSFERRIN SATURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 80052879122     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22153     Document Type: Letter

References (21)

1. Barton JC, Baron EH, Bertoli LF, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to response to or did not tolerate oral iron supplementation. Am J Med 2000; 109: 27-32.
2. Auerbach M, Witt D, Toler W, et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988; 111: 556-570.
3. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307.
4. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996; 7: 2654-2657.
5. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998; 31: 81-86.
6. Auerbach M, Ballard H, Glaspy J. Clinical update: Intravenous iron for anaemia. Lancet 2007; 369: 1502-1504.
7. Mays T, Mays T. Intravenous iron-dextran therapy in the treatment of anemia occurring in surgical, gynecologic and obstetric patients. Surg Gynecol Obstet 1976; 143: 381-384.
8. Malek JT. Total dose imferon infusion using the fixed volume/time technique. Med J Malaysia 1978; 32: 313-315.
9. Johnson CS. Intravenous iron-dextran in the treatment of iron deficient anemia. J Natl Med Assoc 1979; 71: 1101-1105.
10. Low CL, Bailie GR, Eisele G. Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients. Ren Fail 1997; 19: 781-788.
11. Mamula P, Piccoli DA, Peck SN, et al. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 34: 286-290.
12. Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28: 529-534.
13. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. The Oncologist 2007; 12: 231-242.
14. Singh AK, Coyne DW, Shapiro W, et al. Predictors of response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163-1171.
15. Al-Momen AK, Al-Meshari A, Al-Nuaim L, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia in pregnancy. Eur J Obstet Gynecol Reprod Biol 1996; 69: 121-124.
16. Bashiri A, Burstein E, Sheiner E, Mazor M. Anemia during pregnancy and treatment with intravenous iron: Review of the literature. Eur J Obstet Gynecol Reprod Biol 2003; 110: 2-7.
17. Ayub R, Tariq N, Adil MM, et al. Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Phys Surg Pak 2008; 18: 424-427.
18. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion 2009; 49: 19-28.
19. Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: A review of randomized controlled trials across different indications. Arzneimittelforschung 2010; 60: 386-398.
20. FDA Advisory Committee Briefing Document. New Drug Application (NDA) 22-054 for Injectafer (ferric carboxymaltose) for the treatment of iron deficiency anemia in patients with heavy uterine bleeding or postpartum patients. www.fda. gov/ohrms/dockets/ac/08/briefing/2008-4337b1-01-fda.pdf February 1, 2008. Accessed May 6, 2011.
21. Gasche C, Kulnigg S. Intravenous iron in inflammatory bowel disease. Semin Hematol 2006; 43: S18-S22.